Home / Resources / Videos / AACE 2018 / Richard Bergenstal Part 2, CGM for Type 2 Diabetes

Richard Bergenstal Part 2, CGM for Type 2 Diabetes

In part 2 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the educational benefit from using CGM for type 2 diabetes.

Richard Bergenstal MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet Methodist Hospital in Minneapolis, Minnesota.


Transcript of this video segment: CGM for Type 2 Diabetes

Freed: You know, the CGM, it’s really made an impact, especially for type 1s. That is no doubt. The studies have been done. The results are in.

Bergenstal: Yeah.

Freed: Cost is not even a question anymore. You know, it makes a huge difference in a person’s quality of life. Let’s look at type 2s for a second. I foresee type 2s using CGMs whether they’re on insulin or not if the insurance companies ever decided to pay for it. Because I’m a firm believer that if a person eats a piece of cherry pie and they look at their blood sugars they’re — it’s only common sense that you’re going to say, “I can’t eat cherry pie anymore.”

Bergenstal: I can’t eat it as often anyway.

Freed: (Laughs) What are your thoughts of using it for an educational purpose for type 2s?

Bergenstal: Well, I think CGMs is rapidly making its way into the type 2 space right now. So, I mentioned that our diabetes center is sort of integrated into a multispecialty clinic. And so, we work closely with primary care and I must tell you, it’s taken a while but they’re now starting to say, “Why aren’t we looking at blood sugars?” They’ve really been in a mindset of A1C as king and they based all their — now they’re saying, “Yeah, I think you’re right. Looking at these glucoses is interesting.” And when we show them a CGM profile, they are amazed that they never had any idea what it was looking like. Now, you go, take it to a patient. And I agree with you. I think lifestyle modification is going to be a big deal in type 2 diabetes. And then, even medication selection. Moving a patient to start insulin or to start another drug and you can say, “Here is why. Look at your picture. And I’m selecting for you or hopefully with you the next medicine to try to smooth this out. Come back and we’ll look at your profile again in a few weeks and we’ll see if we’re achieving our goal.”

Freed: I can foresee with CGM, with intelligence, that if you ate three Big Macs, it would actually tell you, you did a stupid thing.

Bergenstal: Yeah.  

Freed: And it’ll prevent you from doing things in the future that’s —

Bergenstal: Oh, I think, yeah. The machine learning people, the guide to decision-making people are going to get into the act for sure and say, “Wait, you tried that before. It didn’t work so well,” or, “Here’s what happened.” So, yeah, we’re going to get — this is going to get smarter and smarter. Now, people still have to interact and agree and participate, but at least they can do it from a sense of having actual real data to look at.

Return to the main page.